When interferon-alfa was added to less aggressive treatments, such as single alkylating agents, an overall survival advantage was not observed, although there was evidence of an improvement in disease-free survival.
The efficacy of an intensive combination (ProMace-MOPP) was not improved by the addition of interferon-alfa.